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Abstract
Background: Activating mutations in the GLUD1 gene (which encodes for the intra-mitochondrial
enzyme glutamate dehydrogenase, GDH) cause the hyperinsulinism–hyperammonaemia (HI/HA)
syndrome.Patients present withHA and leucine-sensitivehypoglycaemia. GDH is regulated byanother
intra-mitochondrial enzyme sirtuin 4 (SIRT4). Sirt4 knockout mice demonstrate activation of GDH
with increased amino acid-stimulated insulin secretion.
Objectives: To study the genotype–phenotype correlations in patients with GLUD1 mutations. To report
the phenotype and functional analysis of a novel mutation (P436L) in the GLUD1 gene associated with
the absence of HA.
Patients and methods: Twenty patients with HI from 16 families had mutational analysis of the GLUD1
gene in view of HA (nZ19) or leucine sensitivity (nZ1). Patients negative for a GLUD1 mutation had
sequence analysis of the SIRT4 gene. Functional analysis of the novel P436L GLUD1 mutation was
performed.
Results: Heterozygousmissensemutationsweredetectedin15patientswithHI/HA,2ofwhicharenovel
(N410D and D451V). In addition, a patient with a normal serum ammonia concentration (21 mmol/l)
was heterozygous for a novel missense mutation P436L. Functional analysis of this mutation conﬁrms
that it is associated with a loss of GTP inhibition. Seizure disorder was common (43%) in our cohort of
patients with a GLUD1 mutation. No mutations in the SIRT4 gene were identiﬁed.
Conclusion: Patients with HI due to mutations in the GLUD1 gene may have normal serum ammonia
concentrations.Hence, GLUD1 mutationalanalysismaybeindicatedinpatientswith leucine sensitivity;
even in the absence of HA. A high frequencyof epilepsy (43%) was observed in our patients with GLUD1
mutations.
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Introduction
The hyperinsulinism/hyperammonaemia (HI/HA) syn-
drome is a form of congenital HI (CHI) in which affected
children have recurrent symptomatic hypoglycaemia
together with a persistently elevated serum ammonia
concentration. It has been shown that this disorder is
caused by activating mutations in the GLUD1 gene that
encodes for the intra-mitochondrial enzyme, glutamate
dehydrogenase (GDH) (1). GDH is highly expressed
in the liver, pancreatic b-cells, kidney and the brain (2).
It catalyses the oxidative deamination of glutamate to
a-ketoglutarate and ammonia. In the pancreatic b-cells,
a-ketoglutarate enters the tricarboxylic acid cycle and
leads to insulin exocytosis.
GDH is allosterically activated by leucine and
inhibited by GTP (3). Activating mutations in the
GLUD1 gene reduce the sensitivity of the enzyme to
allosteric inhibition by GTP and ATP (4). The loss of
inhibition by GTP leads to increased leucine-induced
glutamate oxidation to a-ketoglutarate. Hence, leucine
sensitivity is manifested by postprandial hypoglycaemia
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feature of this condition (5). The mechanism of the
persistent HA, a striking and consistent feature of this
condition, is not completely understood.
GDH is also inhibited by sirtuin 4 (SIRT4), an intra-
mitochondrial enzyme (6) that is highly expressed in
the pancreatic islets (6, 7). Hence, SIRT4 would be an
ideal candidate gene to analyse in patients with HI/HA
syndrome, where no mutations in the GLUD1 gene
are found.
In this study, we report the phenotype and genotype
of 20 patients with HI/HA syndrome. We also report a
novel GLUD1 mutation in a patient with severe leucine
sensitivity but a completely normal serum ammonia
concentration. We highlight the high risk of epilepsy in
patients with GLUD1 mutations and we discuss our
ﬁndings of the SIRT4 gene analysis in a cohort of
patients with HI/HA syndrome, where no mutations are
identiﬁed in the GLUD1 gene.
Research design and methods
We studied 20 patients with HI who were referred for
mutational analysis of the GLUD1 gene either in view of
HA (nZ19) or leucine sensitivity (nZ1). Sixteen
patients were unrelated and four were related demon-
strating vertical transmission of disease consistent with
a dominant pattern of inheritance. The diagnosis of HI
was based on diagnostic criteria described previously,
i.e. inappropriately elevated insulin concentrations at
the time of hypoglycaemia with corresponding low
concentrations of plasma b-hydroxybutyrate and fatty
acids. Clinical information (birth weight, age of
presentation, treatment details, seizure history and
family history) was collected from case notes and the
referring clinicians. The clinical characteristics are
presented as means and summarised in Table 1.
The study was approved by the regional ethical
committee and written consent was obtained from the
families.
Molecular genetics
DNA was extracted from peripheral leukocytes using
standard procedures. The exons of the GLUD1 gene,
which encode the catalytic and allosteric domains of
GDH (exons 6, 7, 10, 11 and 12), were ampliﬁed by PCR
(for primer sequences see Supplementary Table 1,
which can be viewed online at http://www.eje-online.
org/supplemental/) and sequenced using BigDye
Terminator v3.1 (Applied Biosystems, Warrington, UK).
Sequencing reactions were analysed on the ABI 3730
(Applied Biosystems) and compared with the published
sequence (M37154) using Mutation Surveyor software
(SoftGenetics, Philadelphia, PA, USA). Mutation testing
was performed on parental samples and microsatellite
analysis of six markers on chromosome 20 was under-
takentoconﬁrmfamilyrelationshipswhenanoveldenovo
mutation was identiﬁed (primers available on request).
When no GLUD1 mutation was identiﬁed, exons 1–3
of the SIRT4 gene were analysed. All exons were
ampliﬁed by PCR using a single set of primers with the
exception of exon 1, which was ampliﬁed in two
overlapping fragments (for primer sequences see
Supplementary Table 1). PCR products were sequenced
and compared with the published sequence
(NM_012240.1) using Mutation Surveyor software
(SoftGenetics).
Functional analysis of GDH activity
Lymphocytes were isolated from peripheral blood of the
patient with the novel P436L mutation and trans-
formed with Epstein–Barr virus to establish lymphoblast
cultures. The activity of GDH in lymphoblast homogen-
ates and the effect of added GTP were determined







(!50 mmol/l) Mutation Novel
A 1 F 2 days 7 years Yes 58–95 R221C (c.833COT) No
B 2 M 24 weeks 1.6 years Yes 258–307 R265K (c.966GOA) No
C 3 F 32 weeks 2.5 years Yes 128 R269H (c.978GOA) No
D 4 M 28 weeks 1.4 years No 165 R269H (c.978GOA) No
E 5 F 24 weeks 2.5 years No 96 R269H (c.978GOA) No
E 6 F 52 weeks 35 years No 78 R269H (c.978GOA) No
E 7 F Not known 56 years No Not known R269H (c.978GOA) No
E 8 M 52 weeks 26 years No 103 R269H (c.978GOA) No
F 9 M 72 weeks 5.9 years No 60–100 R296H (c.978GOA) No
G 10 M 16 weeks 0.9 years No 250 N410T (c.1401AOC) No
H 11 F 1 week 10 years Yes 120 N410D (c.1400AOG) Yes
I 12 F 52 weeks 13.8 years No 21 P436L (c.1479COT) Yes
J 13 F 6 weeks 18 years Yes 244 S445L (c.1506COT) No
K 14 F 1 week 1.6 years Yes 125–161 S445L (c.1506COT) No
L 15 M 8 weeks 4.8 years Yes 150–190 S445L (c.1506COT) No
M 16 F 28 weeks 2.6 years No 73–144 D451V (c.1524AOT) Yes
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25 8C in Tris–0.01 M acetate buffer, pH 8, containing
10 mM EDTA according to the protocol of de Lonlay et al.
(8). Protein was measured according to the method of
Lowry et al. (9).
Results
Molecular genetics
Seven different heterozygous mutations in the GLUD1
gene were identiﬁed in 13 out of 17 screened probands
(76%; see Table 1). Three mutations were novel:
N410D, D451V and P436L. These mutations were not
present in the probands’ unaffected parents and affected
residues were conserved across species. Mutations at
residue N410 have previously been reported in patients
with HI/HA, including one patient within this cohort,
suggesting that N410 is a functionally important
residue.
Two mutations, S445L and R269H, were each
identiﬁed in three unrelated families. All other
mutations were identiﬁed in a single proband. Testing
of unaffected parents demonstrated that the mutation
had arisen de novo in 11 out of 13 probands. For one
patient, with a S445L mutation, a spontaneous
mutation could not be conﬁrmed as DNA was
unavailable from the unaffected father. In a second
patient, the R269H mutation was inherited by the
proband from their affected mother. Testing of further
family members demonstrated that the R269H
mutation was also present in the proband’s maternal
uncle and grandmother, all of whom have HI/HA.
Sequencingof SIRT4 in the four patients referred with
HI/HA and negative for a GLUD1 mutation did not
reveal any mutations. The mean serum ammonia
concentration of this group of patients was
66.7 mmol/l (50–87 mmol/l). All four patients had
diazoxide-responsive HI with no clinical symptoms
suggestive of protein/leucine sensitivity.
Clinical characteristics of patients with
GLUD1 mutation
The clinical characteristics of the 16 patients with a
GLUD1 mutation are summarised in Table 1. The mean
birth weight of our cohort with a mutation was 3133 g
at a mean gestational age of 38.6 weeks. Macrosomia
was not a common feature with birth weight O90th
centile in only three patients. The age of presentation
was delayed (mean of 23.4 weeks) in comparison
with the patients with CHI due to KATP channel
mutations, with only three presenting in the neonatal
period. Two patients were successfully managed with
manipulation of diet alone; all others required treat-
ment with diazoxide. None of our patients required a
pancreatectomy.
Patient 12 presented at 1 year of age with a tonic–
clonic seizure associated with HI (insulin 9.6 mU/l and
blood glucose 1.7 mmol/l). She had a normal serum
ammonia concentration (21 mmol/l) on presentation
and on repeated measurements (30 and 41 mmol/l)
during childhood. She responded to diazoxide and
demonstrated a normal fasting tolerance on a moderate
dose of diazoxide (12–15 mg/kg per day). However, she
continued to experience intermittent hypoglycaemic
episodes in the postprandial period even on a high dose
of diazoxide (15–17 mg/kg per day). She was hence
evaluated for leucine sensitivity at 13 years of age by an
oral leucine tolerance test. Following a fast of 4 h, an
oral dose of 0.15 g/kg L-leucine was administered (10).
Blood glucose and plasma insulin levels were then
measured at K30, 0, 30, 60, 90 and 120 min.
Diazoxide was not discontinued for the purpose of the
test. The test was stopped at 60 min following the oral
leucine load as she developed symptomatic (sweating,
disordered consciousness and blurred vision) hypogly-
caemia with a blood glucose concentration of
2.2 mmol/l and simultaneous plasma insulin concen-
tration of 69.5 mU/l. Sequencing of the GLUD1 gene
was requested in view of the severe leucine sensitivity.
At the age of 13.7 years, she has mild learning
difﬁculties with memory skills and emotional function-
ing being the areas of most concern.
There was a high incidence of seizures in our cohort of
patients with a GLUD1 mutation. Out of 16 patients, 15
presented with seizures and 7 (43%) of them have
developed epilepsy. All of the patients who developed
epilepsy had generalised seizures. Out of seven patients
withepilepsy,sixhadmutationsinexons6and7.Allthree
patients with the mutation S445L developed epilepsy.
GDH activity in lymphoblasts
The activity and allosteric response of GDH in
lymphoblasts from patient 12 were measured. She had
normal basal GDH activities, but the half-maximal
inhibitory concentration of GTP expressed in nmol/l
(IC50) was 470% higher than that of controls (nZ20)
consistent with an excessive activity of GDH.
Discussion
The phenotype of CHI due to mutations in the GLUD1
gene is well characterised. It is reported to be milder, not
usually associated with macrosomia at birth and tends
to escape recognition till later in infancy (4, 5, 11). This
was conﬁrmed in our study where the mean age of
presentation was 23.4 weeks with only 3 out of 17
patients presenting in the neonatal period. Interestingly,
only three patients had a birth weight of O90th centile
and all three had the S445L mutation. This may
indicate that this mutation causes more severe foetal HI
than the other mutations identiﬁed in our cohort.
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with HI/HA syndrome (12, 13). The increased
frequency of epilepsy is thought to be either the result
of a) hypoglycaemic brain injury due to recurrent
hypoglycaemia or b) chronic HA or c) decreased
concentrations of glutamine and the neurotransmitter
g-aminobutyric acid in the brain due to raised GDH
activity (13). Our study conﬁrms that a high risk of
epilepsy is associated with HI due to mutations in the
GLUD1 gene, as 7 out of 16 (43%) of our patients
developed epilepsy. Six out of the seven patients had
mutations in exons 6 and 7; this was consistent with the
study by Bahi-Buisson et al. (14), which reported that
epilepsy is associated more frequently with mutations in
exons 6 and 7. The mechanism of this genotype–
phenotype association according to the location of the
mutations is as yet unclear.
The most consistent feature of the HI due to
mutations in GLUD1 is the persistent HA, and hence
the term ‘HI/HA syndrome’ is used synonymously
with CHI due to GLUD1 mutations (4, 8, 15).I ti s
proposed that HA is the result of excessive GDH activity
in the hepatocytes leading to an increase in the
production of ammonia from glutamate and/or
depletion of glutamate with reduction in the production
of N-acetylglutamate, an allosteric activator essential
for the ﬁrst step of ammonia detoxiﬁcation (16). The
second mechanism is supported by the reduction in the
concentration of blood ammonia on administration of
N-carbamylglutamate (an analogue of N-acetyl-
glutamate) (17, 18). There has been one other report
of two patients (father and son) with HI due to the
R269H mutation in the GLUD1 gene and normal serum
ammonia concentrations (35 and 28 mmol/l) (19).O u r
patient with the novel P436L mutation had a
completely normal serum ammonia concentration
(highest being 41 mm o l / l )t h a tl e dt oad e l a yi n
establishing the molecular diagnosis. If the origin of
the HA is in the liver, it is possible that our patient is
mosaic for the mutation with the mutation beingabsent
or at !50% in the hepatic tissues. And hence this
absence of HA may not be genotype speciﬁc. However,
we cannot prove or disprove this possibility without a
liver/pancreatic biopsy. Similarly, mosaicism may be the
underlying mechanism in our four patients with HI/HA
syndrome and no GLUD1 mutation with the mutation
affecting the liver and pancreas, but not blood.
Enzymatic analysis of the lymphoblastic GDH from
our patient with the P436L mutation showed a loss of
GTP inhibition with the half-maximal inhibitory
concentration of GTP being 470% higher than that of
controls. Loss of GTP inhibition is known to increase
glutamate oxidation in the presence of leucine causing
leucine-sensitive HI, a classical feature of HI/HA
syndrome. This was clinically evident in our patient
with this novel P436L mutation and was conﬁrmed by
the oral leucine tolerance test. The conﬁrmation of
leucine sensitivity prompted us to sequence the GLUD1
gene and led to the molecular diagnosis. This suggests
that analysis of the GLUD1 gene must be considered in
all patients with leucine sensitivity even in the absence
of HA.
This study also reports two other novel mutations
(N410D and D451V) in the GLUD1 gene. N410 is
located in the antenna-like structure connecting to the
pivot helix of the GDH structure. A mutation (N410T)
previously described at the same residue is known to
cause HI/HA (20). D451 is located in the allosteric
domain of the GLUD1 gene, a common site for
mutations causing HI/HA syndrome and hence likely
to be pathogenic by interfering with the allosteric
binding sites. Conservation data suggest that these
residues are functionally important as they are both
well conserved among species.
SIRT4 has been shown to regulate insulin secretion
by repressing the activity of GDH (6). Sirt4 knockout
mice have increased glucose-stimulated and amino
acid-stimulated insulin secretion in comparison with
wild-type mice along with fasting hypoglycaemia in the
male knockout mice. We hypothesised that a loss of
function mutation of SIRT4 will cause a phenotype
similar to gain of function GLUD1 mutations, i.e. HI/HA
syndrome. However, our cohort of HI/HA patients with
no known genetic aetiology is small, and hence the
negative ﬁndings of our studyare not enough to exclude
a putative role of this gene in HI/HA syndrome.
Conclusion
Mutations in the GLUD1 gene are not always associated
with HA; hence mutational analysis of the GLUD1 gene
may be indicated in patients with HI with evidence of
leucine sensitivity even in the absence of HA. GLUD1
gene mutations cause a mild form of CHI associated
with normal birth weight, delayed age at presentation
and a high risk of epilepsy.
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